NCT05665530 2026-01-26
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
Prelude Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cyclacel Pharmaceuticals, Inc.
Rutgers, The State University of New Jersey